{ "ok": true, "cik": "1815903", "ticker": "PTPI", "name": "Petros Pharmaceuticals, Inc.", "filings": [ { "form": "8-K", "filed": "2026-09-30", "items": [ "1.03 Bankruptcy or Receivership", "2.04 Triggering Events That Accelerate a Financial Obligation", "5.02 Departure or Election of Directors; Appointment of Officers" ], "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926112399/0001104659-26-112399-index.htm" }, { "form": "10-Q", "filed": "2026-08-13", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926095979/0001104659-26-095979-index.htm" }, { "form": "8-K", "filed": "2026-06-18", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926075849/0001104659-26-075849-index.htm" }, { "form": "8-K", "filed": "2026-06-05", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers" ], "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926071027/0001104659-26-071027-index.htm" }, { "form": "10-Q", "filed": "2026-05-13", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926060359/0001104659-26-060359-index.htm" }, { "form": "10-K", "filed": "2026-04-15", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/0001104659-26-043822-index.htm" } ], "events12m": 5, "healthWatch": { "window": "last 12 months", "since": "2025-10-01", "signals": [ { "code": "1.03", "label": "Bankruptcy or receivership", "count": 1, "latest": { "filed": "2026-09-30", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926112399/0001104659-26-112399-index.htm" } }, { "code": "NT 10-K", "label": "Late annual report notice", "count": 1, "latest": { "filed": "2026-03-31", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926037800/0001104659-26-037800-index.htm" } }, { "code": "3.01", "label": "Exchange listing notice or transfer", "count": 1, "latest": { "filed": "2025-11-07", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465925108552/0001104659-25-108552-index.htm" } }, { "code": "2.04", "label": "Debt accelerated or triggered", "count": 1, "latest": { "filed": "2026-09-30", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926112399/0001104659-26-112399-index.htm" } }, { "code": "5.02", "label": "Director or officer change", "count": 4, "latest": { "filed": "2026-09-30", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926112399/0001104659-26-112399-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001815903.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1815903" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up Petros Pharmaceuticals, Inc. ($PTPI). Last filing: 8-K (1.03 Bankruptcy or Receivership), 2026-09-30. 5 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2025-09-05.", "auditor": { "changes": [ { "filed": "2025-09-05", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465925087887/0001104659-25-087887-index.htm" }, { "filed": "2025-04-09", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465925033391/0001104659-25-033391-index.htm" } ], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2024-12-31", "revenue": 5112043, "revenueGrowth1y": -0.12200234680340782, "revenueGrowthPerYear": -0.14485417004787549, "yearsOfData": 5, "operatingMargin": -0.905106432007712, "operatingMarginPrior": -2.338793635875864, "netMargin": -2.8009916974485543, "operatingCashFlow": -2603051, "capitalSpending": 24587, "freeCashFlow": -2627638, "researchAndDevelopment": 2615050, "researchShareOfRevenue": 0.5115469490377917, "cash": 1718645, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2020-12-31", "revenue": 9559469 }, { "fiscalYearEnd": "2021-12-31", "revenue": 7811264 }, { "fiscalYearEnd": "2022-12-31", "revenue": 5992054 }, { "fiscalYearEnd": "2023-12-31", "revenue": 5822388 }, { "fiscalYearEnd": "2024-12-31", "revenue": 5112043 } ], "totalEquity": -7467578, "totalAssets": 10635310, "equityRatio": -0.7021495377191638, "returnOnEquity": null, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "latestAudited": { "fiscalYearEnd": "2025-12-31", "revenue": null, "operatingCashFlow": -6734707, "cash": 5136722, "totalEquity": 2870854, "totalAssets": 5163598, "equityRatio": 0.5559793771707248 }, "revenueYearIsOld": true, "earningsPerShare": -83.47, "sharesOutstanding": 321042, "bookValuePerShare": -23.260439444060278, "revenuePerShare": 15.92328418088599, "range80": { "low": 2821741.6475227084, "high": 6767035.263847338, "baseline": 4463342.3139824495, "n": 2483, "band": "b000", "bandLabel": "under $50M", "method": "v4.1", "credibility": 0.5, "growthYears": 4, "ownVolatility": 0.10147455063885708, "classVolatility": 0.3000583276631395, "volatility": 0.22397777169549435 }, "ifPaceHeld": { "low": 2821741.6475227084, "high": 6767035.263847338 } }, "edgarette": "🔖 Exposure: revenue $5.1M (FY2024). Experience: revenue down 12.2% on the year, down 14.5% a year over 4 years; operating margin -90.5%, up from -233.9%. Soundness: equity -70.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.8M and $6.8M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.7M to $7.2M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -90.5% against a -3.8% median; growth -12.2% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Petros Pharmaceuticals, Inc. (PTPI) saw revenue fall 12.2% in FY2024 to $5 million, operating margin -90.5% against a -3.8% median for pharmaceutical preparations, equity -70.2% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Petros Pharmaceuticals, Inc. against its own record and its peers
Operating marginPeer median -3.8%-90.5%Revenue, on the yearPeer median 13.7%-12.2%Equity of assetsPeer median 40.3%-70.2%Gold tick: the median of 118–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 1, "hits": 1, "rate": 1, "method": "v4", "byYear": { "2024": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "caution": "Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2024, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Petros Pharmaceuticals, Inc. (PTPI) saw revenue fall 12.2% in FY2024 to $5 million, operating margin -90.5% against a -3.8% median for pharmaceutical preparations, equity -70.2% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2024-12-31", "revenue": 5112043, "totalDebt": null, "cash": 1718645 }, "experience": { "revenueGrowth1y": -0.12200234680340782, "revenueGrowthPerYear": -0.14485417004787549, "operatingMargin": -0.905106432007712, "operatingMarginPrior": -2.338793635875864, "netMargin": -2.8009916974485543, "freeCashFlow": -2627638 }, "soundness": { "equityRatio": -0.7021495377191638, "returnOnEquity": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": { "filed": "2025-09-05", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465925087887/0001104659-25-087887-index.htm" } }, "healthWatch": { "window": "last 12 months", "since": "2025-10-01", "signals": [ { "code": "1.03", "label": "Bankruptcy or receivership", "count": 1, "latest": { "filed": "2026-09-30", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926112399/0001104659-26-112399-index.htm" } }, { "code": "NT 10-K", "label": "Late annual report notice", "count": 1, "latest": { "filed": "2026-03-31", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926037800/0001104659-26-037800-index.htm" } }, { "code": "3.01", "label": "Exchange listing notice or transfer", "count": 1, "latest": { "filed": "2025-11-07", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465925108552/0001104659-25-108552-index.htm" } }, { "code": "2.04", "label": "Debt accelerated or triggered", "count": 1, "latest": { "filed": "2026-09-30", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926112399/0001104659-26-112399-index.htm" } }, { "code": "5.02", "label": "Director or officer change", "count": 4, "latest": { "filed": "2026-09-30", "url": "https://www.sec.gov/Archives/edgar/data/1815903/000110465926112399/0001104659-26-112399-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": { "low": 2821741.6475227084, "high": 6767035.263847338, "baseline": 4463342.3139824495, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 2483, "sizeBand": "under $50M", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341, "coverageAllYears": 0.6904374799277399, "stressCoverageAllYears": 0.819004992974709, "outcomeYears": [ 2019, 2025 ] }, "credibility": { "weightOnOwnRecord": 0.5, "growthYears": 4, "ownVolatility": 0.10147455063885708, "classVolatility": 0.3000583276631395, "pricedVolatility": 0.22397777169549435, "k": 3 }, "stress": { "low": 2657459.374495941, "high": 7200364.853871667, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a statistical range, not company guidance; no view on the share price", "track": { "backtest": { "tests": 1, "hits": 1, "rate": 1, "method": "v4", "byYear": { "2024": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": null, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2024, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001815903.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1815903" }, "speedCash": { "fiscalYear": 2024, "cashConversion": -0.5092, "growth3y": -0.1318, "volatility": 0.1015, "paysDividend": false, "raisedDividend": false, "equityRatio": -0.7021, "quadrant": { "code": "ss", "label": "Slow and steady", "plain": "growing slower than its size class, with steadier revenue" }, "compass": { "code": "between", "inside": "Turns -50.9% of revenue into operating cash; revenue shrinking 13.2% a year over three years; no common dividend; liabilities exceed assets.", "outside": "Among under $50M companies: 42nd percentile for cash, 26th for growth.", "emoji": "🌊", "label": "In between", "plain": "no clear cash pattern yet" }, "band": "under $50M", "cashPctInClass": 42, "growthPctInClass": 26, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "warning", "text": "filed bankruptcy or receivership, late annual report notice, debt accelerated or triggered in the last 12 months" }, { "key": "balance", "text": "liabilities exceed assets (often from years of share buybacks, not always distress)" }, { "key": "cash", "text": "operating cash flow was negative" }, { "key": "range", "text": "revenue is hard to predict: its 80% range is ±41%" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 4, "name": "Rotting at the dock", "plain": "four or more warning signs" }, "cashFlow": { "fiscalYearEnd": "2024-12-31", "operating": -2603051, "investing": -24587, "financing": -6999366, "capitalSpending": 24587, "free": -2627638, "trend": [ { "fiscalYearEnd": "2020-12-31", "operating": -15305325, "free": -15309958 }, { "fiscalYearEnd": "2021-12-31", "operating": -11862031, "free": null }, { "fiscalYearEnd": "2022-12-31", "operating": -12797325, "free": null }, { "fiscalYearEnd": "2023-12-31", "operating": -7626529, "free": null }, { "fiscalYearEnd": "2024-12-31", "operating": -2603051, "free": -2627638 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2024-12-31", "cash": 1718645, "shortTerm": null, "longTerm": null, "equityHoldings": null, "totalAssets": 10635310, "ladder": null, "currentRatio": 0.4, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": { "fiscalYear": 2024, "cashConversion": -0.5092, "growth3y": -0.1318, "volatility": 0.1015, "paysDividend": false, "raisedDividend": false, "equityRatio": -0.7021, "quadrant": { "code": "ss", "label": "Slow and steady", "plain": "growing slower than its size class, with steadier revenue" }, "compass": { "code": "between", "inside": "Turns -50.9% of revenue into operating cash; revenue shrinking 13.2% a year over three years; no common dividend; liabilities exceed assets.", "outside": "Among under $50M companies: 42nd percentile for cash, 26th for growth.", "emoji": "🌊", "label": "In between", "plain": "no clear cash pattern yet" }, "band": "under $50M", "cashPctInClass": 42, "growthPctInClass": 26, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "warning", "text": "filed bankruptcy or receivership, late annual report notice, debt accelerated or triggered in the last 12 months" }, { "key": "balance", "text": "liabilities exceed assets (often from years of share buybacks, not always distress)" }, { "key": "cash", "text": "operating cash flow was negative" }, { "key": "range", "text": "revenue is hard to predict: its 80% range is ±41%" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 4, "name": "Rotting at the dock", "plain": "four or more warning signs" }, "cashFlow": { "fiscalYearEnd": "2024-12-31", "operating": -2603051, "investing": -24587, "financing": -6999366, "capitalSpending": 24587, "free": -2627638, "trend": [ { "fiscalYearEnd": "2020-12-31", "operating": -15305325, "free": -15309958 }, { "fiscalYearEnd": "2021-12-31", "operating": -11862031, "free": null }, { "fiscalYearEnd": "2022-12-31", "operating": -12797325, "free": null }, { "fiscalYearEnd": "2023-12-31", "operating": -7626529, "free": null }, { "fiscalYearEnd": "2024-12-31", "operating": -2603051, "free": -2627638 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2024-12-31", "cash": 1718645, "shortTerm": null, "longTerm": null, "equityHoldings": null, "totalAssets": 10635310, "ladder": null, "currentRatio": 0.4, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }